Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 6/20 | 0.34 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404026 | 1.00 | MAPK1 (0.40) | MAPK1SMN1; SMN2ALDH1A1MAOBMAOA | |
| SCHEMBL21153824 | 1.00 | MAPK1 (0.40) | MAPK1SMN1; SMN2ALDH1A1MAOBMAOA | |
| SCHEMBL1286642 | 1.00 | MAPK1 (0.40) | MAPK1SMN1; SMN2ALDH1A1MAOBMAOA | |
| SCHEMBL6023016 | 0.84 | CXCR3 (0.35) | MAPK1SMN1; SMN2ALDH1A1MAOBMAOA | |
| SCHEMBL2478791 | 0.82 | SLC6A2 (0.40) | SMN1; SMN2MAOBMAOAKCNH2HSD11B1 | |
| SCHEMBL2481548 | 0.82 | MAOB (0.38) | MAPK1ALDH1A1MAOBMAOAMEN1 | |
| SCHEMBL2477286 | 0.82 | MAOB (0.38) | MAPK1ALDH1A1MAOBMAOAMEN1 | |
| SCHEMBL2481090 | 0.82 | MAOB (0.39) | MAOBMAOAMEN1KMT2AHSD11B1 | |
| SCHEMBL2482801 | 0.82 | MAOB (0.39) | MAOBMAOAMEN1KMT2AHSD11B1 | |
| SCHEMBL10992027 | 0.82 | SLC6A2 (0.40) | SMN1; SMN2MAOBMAOAKCNH2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805936-A1 | Process for preparing levomilnacipran HCL | Cosma S.p.A. (IT) | 2014-11-26 | — | — | EP | claimed |
| US-20140343322-A1 | PROCESS FOR PREPARING LEVOMILNACIPRAN HCL | COSMA S.P.A. (IT) | 2014-11-20 | — | — | US | claimed |
| CN-115304568-B | Asymmetric synthesis method of 6-azidomethylene-1-aryl-3-oxabicyclo [3,1,0] hex-2-one | 扬州大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-115304568-A | Asymmetric synthesis method of 6-azidomethylene-1-aryl-3-oxabicyclo [3,1,0] hexan-2-ketone | 扬州大学 | 2022-11-08 | — | — | CN | disclosed |
| US-11008596-B2 | Cytochrome P450 BM3 enzyme variants for preparation of cyclopropanes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008596-B2 | Cytochrome P450 BM3 enzyme variants for preparation of cyclopropanes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190211367-A1 | VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3230258-B1 | PROCESS FOR THE PREPARATION OF (1S,2R)-MILNACIPRAN | QUIM SINTETICA S A (ES) | 2019-06-26 | — | — | EP | disclosed |
| EP-3230258-B1 | PROCESS FOR THE PREPARATION OF (1S,2R)-MILNACIPRAN | QUIM SINTETICA S A (ES) | 2019-06-26 | — | — | EP | disclosed |
| US-10208322-B2 | In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-02-19 | — | — | US | disclosed |
| US-10131624-B2 | Process for the preparation of (1S,2R)-Milnacipran | QUIMICA SINTETICA, S.A. (ES) | 2018-11-20 | — | — | US | disclosed |
| WO-2011158249-A1 | PROCESS FOR PREPARATION OF MILNACIPRAN INTERMEDIATE AND ITS USE IN PREPARATION OF PURE MILNACIPRAN | GLENMARK GENERICS LIMITED (IN) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011158249-A1 | PROCESS FOR PREPARATION OF MILNACIPRAN INTERMEDIATE AND ITS USE IN PREPARATION OF PURE MILNACIPRAN | GLENMARK GENERICS LIMITED (IN) | 2011-12-22 | — | — | WO | disclosed |
| US-20110295036-A1 | METHOD FOR SYNTHESIS OF (1S, 2R)-MILNACIPRAN | PIERRE FABRE MEDICAMENT (FR) | 2011-12-01 | — | — | US | disclosed |
| US-20110295036-A1 | METHOD FOR SYNTHESIS OF (1S, 2R)-MILNACIPRAN | PIERRE FABRE MEDICAMENT (FR) | 2011-12-01 | — | — | US | disclosed |
| EP-1656349-B1 | CYCLOPROPYL DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2011-10-12 | — | — | EP | disclosed |
| US-7834008-B2 | neurokinin receptor 3 (NK3) antagonists; psychological disorders, inflammatory bowel disease, asthma, ischemia, Parkinson's disease; e.g. (1S,2R)-2-(4-Acetylamino-4-phenyl-piperidin-1-ylmethyl)-1-(3,4-dichlorophenyl)-cyclopropanecarboxylic acid, benzyl-methyl-amide | H. LUNDBECK A/S (DK) | 2010-11-16 | — | — | US | disclosed |
| WO-2010086394-A1 | METHOD FOR SYNTHESIS OF (1S, 2R)-MILNACIPRAN | PIERRE FABRE MEDICAMENT (FR) | 2010-08-05 | — | — | WO | disclosed |
| US-7309799-B2 | Methods for the synthesis of milnacipran and congeners thereof | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2007-12-18 | — | — | US | disclosed |
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | H. LUNDBECK A/S (DK) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131624-B2 | Process for the preparation of (1S,2R)-Milnacipran | HTR5A, HTR1A, HTR4 | MAPK1 2466/4885SMN1; SMN2 1839/4885ALDH1A1 704/4885 |
| US-20140343322-A1 | PROCESS FOR PREPARING LEVOMILNACIPRAN HCL | TNNT2, SSTR2, TNNC1 | MAPK1 1509/4885SMN1; SMN2 1512/4885ALDH1A1 2132/4885 |
| US-20110295036-A1 | METHOD FOR SYNTHESIS OF (1S, 2R)-MILNACIPRAN | LCT, AGTR2, SLC28A2 | MAPK1 3761/4885SMN1; SMN2 3905/4885ALDH1A1 290/4885 |
| US-20060281746-A1 | Cyclopropyl derivatives as nk3 receptor antagonists | TACR2, SLC6A3, TACR1 | MAPK1 1121/4885SMN1; SMN2 4400/4885ALDH1A1 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.